|
||||
|
Product trade name: Valsacor
Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products: Valsacor available forms, composition, doses: Valsacor destination | category: Indications and usages, anatomical therapeutic chemical and diseases classification codes: Pharmaceutical companies, researchers, developers, manufacturers, distributors and suppliers: Online pharmacy, drugstores, pharma, health and beauty shops selling this or related pharmaceutical products: There is an additional general information about this medication active ingredient valsartan: Pharmacological action Valsacor is an antihypertensive drug. This medication is a specific antagonist of angiotensin II. It has a selective antagonistic effect on AT1-receptors, which are responsible for implementing the effects of angiotensin II. Due to the blockade of AT1-receptors the plasma concentrations of angiotensin II increased, which may stimulate the unblocked AT2-receptors. This medicine has no agonistic activity against AT1-receptor. The affinity of valsartan for AT1-receptors in about 20 000 times higher than that of AT2-receptors. Valsacor does not inhibit ACE. This drug has no interaction and does not block other hormone receptors or ion channels important for regulation of the cardiovascular system. This medication has no effect on total cholesterol, triglycerides, glucose and uric acid in blood plasma. A start of antihypertensive action of valsartan after its oral administration in a single dose occurs within 2 h after administration, the maximum effect is achieved within 4-6 h. Pharmacokinetics After oral administration Valsacor is rapidly absorbed from the gastrointestinal tract, the extent of absorption is characterized by individual differences. The absolute bioavailability is average 23%. In course of treatment with this medication there were not noted changes of pharmacokinetic parameters. When administered with food valsartan AUC decreased by 48%, with approximately 8 hours after administration of valsartan in plasma concentrations of the same in patients taking it with food and fasting. AUC decrease is not accompanied by clinically significant reduction in therapeutic effect. When you receive valsartan 1 time / day the accumulation is expressed only slightly. The concentration of valsartan in the blood plasma of women and men were equal. The binding with plasma proteins, primarily to albumin is 94-97%. The plasma clearance of valsartan is about 2 L / h. This medication is excreted in the feces 70% and in urine 30%, largely unchanged. When biliary cirrhosis or biliary obstruction AUC of valsartan is increased approximately 2-fold. Why is Valsacor prescribed? A treatment of hypertension. A treatment of chronic heart failure (II-IV functional class classification NYHA) in patients receiving conventional therapy with diuretics, digitalis preparations, as well as ACE inhibitors or beta-blockers. Dosage and administration Valsacor is taken orally in dose 80 mg daily 1 time / day or 40 mg 2 times / day. In the absence of adequate effect the daily dose may be gradually increased. The maximum daily dose is 320 mg in 2 divided doses. Valsacor side effects, adverse reactions Cardiovascular system: hypotension, postural dizziness, postural hypotension. CNS: dizziness, headache. Digestive system: diarrhea, nausea, increased bilirubin levels. Urinary system: rarely - renal failure, increased creatinine and BUN (especially in chronic heart failure). Metabolic: hyperkalemia. Hematopoietic system: neutropenia, a decrease in hemoglobin and hematocrit. Allergic reactions: rarely - angioedema, rash, pruritus, serum sickness, vasculitis. Other: fatigue, weakness, cough, sore throat, increased risk of viral infections. Valsacor contraindications Pregnancy, hypersensitivity to valsartan. Using during pregnancy and breastfeeding Valsacor is contraindicated during pregnancy. It is not known whether valsartan is allocated to breast milk in humans. Use during lactation (breastfeeding) is not recommended. Experimental studies have shown that this medication is excreted in breast milk of rats. Category of the fetus by FDA - D. Special instructions When hyponatremia and / or reduction of the BCC, as well as during treatment with high doses of diuretics, valsartan, in rare cases can cause pronounced hypotension. Before starting treatment it should be the correction of violations of water-salt metabolism. In patients with renovascular hypertension, which developed secondary to renal artery stenosis, in the period of treatment should regularly monitor the level of urea and creatinine in serum. There is no data on the safety of patients with CC than 10 ml / min. With great caution use in patients with impaired patency of the biliary tract. Due to inhibition of the RAAS in patients predisposed to changes in renal function. With use of ACE inhibitors and angiotensin receptor antagonists in patients with chronic heart failure severity of the observed oliguria and / or increase azotemia, rarely developed acute renal failure with risk of death. Safety and efficacy of valsartan in children has not been established. If use Valsacor it is recommended a caution when driving and management mechanisms. Valsacor drug interactions When this drug applied simultaneously with: - diuretics in high doses it may developed hypotension. - potassium-sparing diuretics, heparin, dietary supplements or salt substitutes containing potassium may develop hyperkalemia. - indomethacin may decrease the antihypertensive action of Valsacor. - lithium carbonate, described the case of lithium toxicity. Valsacor in case of emergency / overdose Symptoms: hypotension, tachycardia or bradycardia. Treatment: symptomatic therapy, dialysis is not effective.
Comments
|
|
|||
|
||||